{
    "nct_id": "NCT04995653",
    "official_title": "A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)",
    "inclusion_criteria": "* Male and female subjects â‰¥ 18 years of age undergoing HSCT.\n* Planning to undergo allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen matched related donor, haploidentical related donor, HLA-matched unrelated donor, or HLA 1-antigen mismatched unrelated or related donor, with either bone marrow or peripheral blood stem cells as a graft source, and with any conditioning regimen\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Severe colitis of any etiology or active/currently-treated inflammatory bowel disease (IBD) or total colectomy.\n* Evidence of relapse or progression of hematologic malignancy (minimal residual disease is allowed).\n* Transplant using umbilical cord blood or ex vivo T-cell-depleted HSCT\n* Receipt of chimeric antigen receptor T-cell (CAR-T) therapy.\n* Received a fecal microbiota transplant (FMT) or any live microbial therapeutic within 3 months prior to Screening.\n* Known allergy or intolerance to oral vancomycin.\n* Concomitant participation or participation within 14 days or 5 half-lives of another investigational unapproved treatment, whichever is longer.",
    "miscellaneous_criteria": ""
}